Stoke Therapeutics’ (STOK) “Buy” Rating Reaffirmed at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report issued on Thursday, Benzinga reports. They presently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 72.28% from the company’s previous close.

A number of other research firms also recently issued reports on STOK. JPMorgan Chase & Co. increased their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 26th. Wedbush increased their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. Finally, Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $19.63.

Stoke Therapeutics Stock Down 5.4 %

STOK stock opened at $12.77 on Thursday. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $16.40. The company has a market cap of $591.25 million, a price-to-earnings ratio of -5.39 and a beta of 0.77. The company has a 50 day moving average of $8.01 and a two-hundred day moving average of $5.71.

Insider Activity at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 5,126 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $13.20, for a total value of $67,663.20. Following the transaction, the general counsel now directly owns 2,598 shares in the company, valued at approximately $34,293.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, General Counsel Jonathan Allan sold 5,126 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $13.20, for a total value of $67,663.20. Following the transaction, the general counsel now directly owns 2,598 shares in the company, valued at approximately $34,293.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares in the company, valued at $126,550.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,741 shares of company stock worth $223,115. 12.30% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Stoke Therapeutics by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock valued at $8,671,000 after purchasing an additional 17,814 shares during the period. Barclays PLC boosted its holdings in Stoke Therapeutics by 365.3% in the 4th quarter. Barclays PLC now owns 39,271 shares of the company’s stock valued at $206,000 after purchasing an additional 30,831 shares during the period. Granahan Investment Management LLC lifted its holdings in shares of Stoke Therapeutics by 33.7% during the 4th quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock worth $5,985,000 after acquiring an additional 286,686 shares during the period. Bridgeway Capital Management LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth about $90,000. Finally, Birchview Capital LP lifted its holdings in shares of Stoke Therapeutics by 147.1% during the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.